Table 2.
Outcomes of the second screening round in first round participants (tested with a low [15 μg Hb/g feces] or high [47 μg Hb/g feces] cut‐off level) and in first round non‐participants
| Participation rate | Positivity rate | PPV CRC | PPV AA | Detection rate CRC | Detection rate AA | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | ‰ | n | ‰ | |
| Previous participants | ||||||||||||
| Total | 325,392 | 93.5 (93.4–93.6) | 13,743 | 4.2 (4.2–4.3) | 708 | 6.1 (5.7–6.6) | 3,996 | 34.6 (33.8–35.5) | 708 | 2.2 (2.0–2.3) | 3,996 | 12.3 (11.9–12.7) |
| Adjusted1 | 93.5 | 4.2 | 6.1 | 34.6 | 2.2 | 12.3 | ||||||
| FIT (15,47) | ||||||||||||
| Total | 39,257 | 94.1 (93.8–94.3) | 1,303 | 3.3 (3.1–3.5) | 63 | 5.7 (4.5–7.2) | 344 | 31.2 (28.5–34.0) | 63 | 1.6 (1.3–2.1) | 344 | 8.8 (7.9–9.7) |
| Adjusted1 | 3.42 | 5.5 | 30.5 | 1.6 | 8.82 | |||||||
| Gender | ||||||||||||
| Men | 18,497 | 94.0 (93.7–94.4) | 732 | 4.0 (3.7–4.2) | 36 | 5.8 (4.2–7.9) | 209 | 33.7 (30.0–37.5) | 36 | 1.9 (1.4–2.7) | 209 | 11.3 (9.9–12.9) |
| Women | 20,760 | 94.0 (93.7–94.3) | 571 | 2.8 (2.5–3.0) | 27 | 5.6 (3.9–8.0) | 135 | 28.0 (24.2–32.2) | 27 | 1.3 (0.9–1.9) | 135 | 6.5 (5.5–7.7) |
| Age | ||||||||||||
| 65 | 1,953 | 94.5 (93.5–95.4) | 67 | 3.4 (2.7–4.3) | 2 | 3.6 (1.0–12.1) | 15 | 26.8 (17.0–39.6) | 2 | 1.0 (0.3–3.7) | 15 | 7.7 (4.7–12.6) |
| 67 | 23,874 | 94.0 (93.7–94.3) | 741 | 3.1 (2.9–3.3) | 32 | 5.1 (3.7–7.2) | 191 | 30.7 (27.2–34.4) | 32 | 1.3 (0.9–1.9) | 191 | 8.0 (6.9–9.2) |
| 69 | 13,430 | 94.1 (93.7–94.5) | 495 | 3.7 (3.4–4.0) | 29 | 6.8 (4.8–9.6) | 138 | 32.5 (28.2–37.1) | 29 | 2.2 (1.5–3.1) | 138 | 10.3 (8.7–12.1) |
| FIT (47,47) | ||||||||||||
| Total | 286,135 | 93.4 (93.3–93.5) | 12,440 | 4.3 (4.3–4.4) | 645 | 6.2 (5.7–6.7) | 3,652 | 35.0 (34.1–35.9) | 645 | 2.3 (2.1–2.4) | 3,652 | 12.8 (12.4–13.2) |
| Adjusted1 | 4.42 | 6.3 | 35.2 | 2.3 | 13.02 | |||||||
| Gender | ||||||||||||
| Men | 138,117 | 93.4 (93.3–93.5) | 7,108 | 5.1 (5.0–5.3) | 373 | 6.2 (5.6–6.9) | 2,269 | 37.9 (36.7–39.1) | 373 | 2.7 (2.4–3.0) | 2,269 | 16.4 (15.8–17.1) |
| Women | 148,018 | 93.4 (93.2–93.5) | 5,332 | 3.6 (3.5–3.7) | 272 | 6.1 (5.5–6.9) | 1,383 | 31.1 (29.8–32.5) | 272 | 1.8 (1.6–2.1) | 1,383 | 9.3 (8.9–9.8) |
| Age | ||||||||||||
| 62 | 23,875 | 93.0 (92.7–93.3) | 910 | 3.8 (3.6–4.1) | 36 | 4.8 (3.5–6.5) | 248 | 32.9 (29.7–36.4) | 36 | 1.5 (1.1–2.1) | 248 | 10.4 (9.2–11.8) |
| 65 | 76,776 | 93.6 (93.4–93.8) | 3,087 | 4.0 (3.9–4.2) | 152 | 5.8 (5.0–6.8) | 895 | 34.3 (32.5–36.2) | 152 | 2.0 (1.7–2.3) | 895 | 11.7 (10.9–12.4) |
| 67 | 77,209 | 93.5 (93.3–93.6) | 3,387 | 4.4 (4.2–4.5) | 151 | 5.3 (4.5–6.2) | 994 | 34.8 (33.1–36.6) | 151 | 2.0 (1.7–2.3) | 994 | 12.9 (12.1–13.7) |
| 69 | 108,275 | 93.3 (93.2–93.5) | 5,056 | 4.7 (4.5–7.8) | 306 | 7.3 (6.5–8.1) | 1,515 | 35.9 (34.5–37.4) | 306 | 2.8 (2.5–3.2) | 1,515 | 14.0 (13.3–14.7) |
| Previous non‐participants | ||||||||||||
| Total | 23,499 | 21.0 (20.8–21.3) | 1,850 | 7.9 (7.6–8.3) | 124 | 9.7 (8.2–11.4) | 580 | 45.2 (42.5–48.0) | 124 | 5.3 (4.5–6.3) | 580 | 24.8 (22.8–26.8) |
| Adjusted1 | 21.03 | 7.93 | 9.83 | 45.33 | 5.43 | 24.83 | ||||||
| Gender | ||||||||||||
| Men | 12,302 | 20.3 (19.9–20.6) | 1,158 | 9.4 (8.9–10.0) | 86 | 10.4 (8.5–12.7) | 400 | 48.5 (45.1–52.0) | 86 | 7.0 (5.7–8.7) | 400 | 32.6 (29.6–35.9) |
| Women | 11,197 | 22.0 (21.6–22.3) | 692 | 6.2 (5.8–6.7) | 38 | 8.3 (6.1–11.2) | 180 | 39.3 (34.9–43.8) | 38 | 3.4 (2.5–4.7) | 180 | 16.1 (14.0–18.6) |
| Age | ||||||||||||
| 62 | 2,152 | 21.4 (20.6–22.2) | 154 | 7.2 (6.2–8.3) | 4 | 3.6 (1.4–9.0) | 48 | 43.6 (34.7–53.0) | 4 | 1.9 (0.7–4.8) | 48 | 22.4 (16.9–29.5) |
| 65 | 5,713 | 21.5 (21.0–22.0) | 418 | 7.3 (6.7–8.1) | 32 | 10.7 (7.7–14.8) | 138 | 46.3 (40.7–52.0) | 32 | 5.6 (4.0–7.9) | 138 | 24.2 (20.6–28.6) |
| 67 | 7,165 | 20.9 (20.5–21.3) | 551 | 7.7 (7.1–8.4) | 39 | 10.2 (7.5–13.6) | 175 | 45.7 (40.8–50.7) | 39 | 5.5 (4.0–7.5) | 175 | 24.5 (21.2–28.4) |
| 69 | 8,469 | 20.8 (20.4–21.2) | 727 | 8.6 (8.0–9.2) | 49 | 10.0 (7.6–12.9) | 219 | 44.6 (40.3–49.0) | 49 | 5.8 (4.4–7.7) | 219 | 25.9 (22.7–29.5) |
Note: Because of small numbers, the results of the age categories of 66 (n = 1) and 72 (n = 1) years old in the non‐participants of the first round are not shown.
1
Age‐adjusted rates.
2
Significant (α = 0.05) difference between used FIT cut‐offs in the first round.
3
Significantly (α = 0.05) different compared to previous participants.
Abbreviations: AA, advanced adenoma; CRC, colorectal cancer; PPV, positive predictive value.